SCHEMBL7225535

SCHEMBL7225535

C[C@H]1CN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2CC[C@@H]4C)C[C@H](C)C1O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.77
KDM4E B2RXH2 9/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CYP1A2 P05177 1/20 0.56
ALDH1A1 P00352 6/20 0.50
HPGD P15428 5/20 0.50
HSD17B10 Q99714 4/20 0.50
ALB P02768 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
POLB P06746 3/20 0.49
AADAT Q8N5Z0 2/20 0.49
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49
TUBA1B P68363 1/20 0.49
TUBA4A P68366 1/20 0.49
TUBB4B P68371 1/20 0.49
TUBB3 Q13509 1/20 0.49
TUBB2A Q13885 1/20 0.49
TUBB8 Q3ZCM7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7236649 1.00 LMNA (0.77) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7226923 1.00 LMNA (0.77) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7762057 0.90 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL4369351 0.90 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL4369898 0.90 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL4379656 0.90 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
Water SCHEMBL7764910 0.89 LMNA (0.78) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7226200 0.88 LMNA (0.71) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
Nadifloxacin SCHEMBL3818938 0.87 LMNA (1.00) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
Nadifloxacin SCHEMBL29429713 0.87 LMNA (1.00) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 US claimed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 US claimed
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 US disclosed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment ALPI, POLR1C, POLI LMNA 1788/4885KDM4E 2308/4885SMN1; SMN2 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.